Latest news with #DilipShanghvi
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Sun Pharma lines up $100 mn to commercialise niche products in FY26
Sun Pharmaceutical Industries has lined up a $100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said. The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
Economic Times
2 days ago
- Business
- Economic Times
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added. (You can now subscribe to our Economic Times WhatsApp channel)
New Indian Express
3 days ago
- Business
- New Indian Express
Sun Pharma's Checkpoint buy: Why it's a strategic fit in the new SPIL focus
CHENNAI: India's largest drug maker, Sun Pharmaceutical Industries, has completed its acquisition of US-based Checkpoint Therapeutics for approximately $355 million. This strategic move significantly strengthens Sun Pharma's oncology and dermatology portfolio, aligning with its focus on high-value specialty therapies. Despite the long-term strategic value, the market reaction on Friday surprised many, as Sun Pharma's share price fell by 1.46% at the close of the week's trading. This dip may have been driven by immediate concerns, including regulatory issues at a key manufacturing facility and the company's cautious financial guidance. Investors are closely monitoring developments—particularly the US FDA's observations regarding Sun Pharma's Dahej facility. The company's financial performance in the coming quarters will also be under scrutiny as stakeholders assess the potential impact on its stock trajectory. Strategic Rationale and Synergies of the Checkpoint Deal Drug industry analysts believe the Checkpoint acquisition is a major strategic gain for Sun Pharma, which has historically grown through carefully chosen, high-potential acquisitions. According to analysts at HDFC Securities, the deal aligns with Sun Pharma's capital allocation strategy to strengthen its specialty business. Checkpoint's Unloxcyt—a novel skin cancer drug—will serve as a complementary addition to its oncology portfolio. In the post-Q4 earnings call, Chairman and Managing Director Dilip Shanghvi reiterated the company's commitment to expanding its specialty business. Sun Pharma's specialty and innovative therapeutics division currently focuses on dermatology, ophthalmology, and oncology. Unloxcyt will complement existing products such as Odomzo (sonidegib) and Yonsa (abiraterone acetate)—both approved in the US—Nidlegy (awaiting approval in the EU), and the recently acquired Fibromun (in Phase III trials). Other specialty molecules in development, including Ilumya (for psoriatic arthritis), GL0034 (obesity), MM-II (osteoarthritis), SCD-044 (atopic dermatitis/psoriasis), and Fibromun (for soft tissue sarcoma/glioblastoma), offer long-term growth potential. According to analysts, the Checkpoint acquisition is strategically significant for four key reasons:
Associated Press
4 days ago
- Business
- Associated Press
Sun Pharma Completes its Acquisition of Checkpoint Therapeutics
MUMBAI, India and PRINCETON, N.J., May 30, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, 'Sun Pharma')) today announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc. ('Checkpoint'), an immunotherapy and targeted oncology company. As part of the acquisition, Sun Pharma acquires UNLOXCYT™, the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma. 'This acquisition exemplifies Sun Pharma's commitment to supporting patients and growing its innovative therapies business,' said Dilip Shanghvi, Chairman & Managing Director of Sun Pharma. 'By adding UNLOXCYT™, we will be able to leverage our leadership in the onco-derm space to help patients access an important treatment option while growing our product portfolio.' Financial Terms Sun Pharma has acquired all outstanding shares of Checkpoint at a price of $4.10 per share in cash, without interest, plus one non-tradable contingent value right (CVR) per share representing the right to receive up to an additional $0.70 in cash, without interest, if certain specified milestones are met, as set out in the terms and conditions of the contingent value rights agreement. About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050) Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit and follow us on LinkedIn & X (Formerly Twitter). About Cutaneous Squamous Cell Carcinoma Cutaneous squamous cell carcinoma ('cSCC') is the second-most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1.8 million cases according to the Skin Cancer Foundation. Important risk factors for cSCC include chronic ultraviolet exposure and immunosuppressive conditions. While most cases are localized tumors amenable to curative resection, each year approximately 40,000 cases become advanced and an estimated 15,000 people in the United States die from this disease. In addition to being a life-threatening disease, cSCC causes significant functional morbidities and cosmetic deformities due to tumors that commonly arise in the head and neck region, and that invade blood vessels, nerves and vital organs, such as the eye or ear. UNLOXCYT™ INDICATION and IMPORANT SAFETY INFORMATION INDICATION UNLOXCYT™ (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. IMPORTANT SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions Immune-Mediated Pneumonitis Immune-Mediated Colitis Immune-Mediated Hepatitis Immune-Mediated Endocrinopathies Adrenal Insufficiency Hypophysitis Thyroid Disorders Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis Immune-Mediated Nephritis with Renal Dysfunction Immune-Mediated Dermatologic Adverse Reactions Other Immune-Mediated Adverse Reactions Infusion-Related Reactions Complications of Allogeneic HSCT Embryo-Fetal Toxicity Common Adverse Reactions The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, and urinary tract infection. Please see full Prescribing Information. Sun Pharma Contacts: Investors Dr. Abhishek Sharma +91 22 4324 2929 [email protected] Media (Global) Gaurav Chugh +91 22 4324 5373 [email protected] Media (USA) James Freeman +1 978-808-6956 [email protected] View original content to download multimedia: SOURCE Sun Pharma
Business Standard
23-05-2025
- Business
- Business Standard
Sun Pharma drops after Q4 PAT slides 19% YoY to Rs 2,1450 cr
Sun Pharmaceutical Industries declined 3.08% to Rs 1,667 after the company's consolidated net profit declined 19% to Rs 2,149.88 crore, despite of 8.5% increase in revenue from operations to Rs 12,815.58 crore in Q4 FY25 over Q4 FY24. Profit before tax (PBT) jumped 15.6% YoY to Rs 3,254.35 crore in Q4 FY25. During the quarter, EBITDA stood at Rs 3,716.1 crore (including other operating revenues), up 22.4% with resulting EBITDA margin of 28.7%. India formulations sales were Rs 4,213 crore for Q4FY25, a growth of 13.6% over Q4 last year and accounted for 32.9% of total consolidated sales for the quarter. US formulation sales were $464 million for Q4FY25, lower by 2.5% over Q4 FY24 and accounted for 31.4% of total consolidated sales for the quarter. Formulation sales in emerging markets sales were $261 million for Q4FY25, a growth of 6.3% over Q4 last year and accounted for 17.6% of total consolidated sales for the quarter. Formulation sales in Rest of World (RoW) markets were $ 200 million for Q4FY25, a growth of 2.0% over Q4 FY24 and accounted for approximately 13.5% of total consolidated sales for the quarter. During the quarter, external sales of API were at Rs 533 crore, up 28.2%. The company said that its API portfolio supports its formulation business and API customers across geographies. During the quarter, R&D expense stood at Rs 816.6 crore, or 6.4% of sales. On full year basis, the companys consolidated net profit jumped 14.1% to Rs 10,929.04 crore on 9% increase in revenue from operations to Rs 52,041.25 crore in FY25 over FY24. The pharmaceutical company stated that it has a comprehensive product offering in the US market consisting of approved ANDAs for 542 products while filings for 117 ANDAs await US FDA approval, including 33 tentative approvals. Additionally, the portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval. For the quarter, 9 ANDA were filed and 1 ANDA approval was received. Dilip Shanghvi, chairman and managing director of the company said, Our businesses delivered a robust performance for the year, driven by improving market share in India and growth in Global Specialty. The near-term pipeline in Global Specialty is promising, with products such as Leqselvi and Unloxcytthe latter through our recently announced checkpoint acquisitionoffering significant improvements in patient care. We look forward to specialty becoming an increasingly important part of our business. Meanwhile, the companys board recommended a final dividend of Rs 5.50 per share with a face value of Rs 1 each for FY25, subject to approval of shareholders approval at the ensuing annual general meeting (AGM). The company has fixed the record date as Monday, 7 July 2025. If the dividend approved by shareholders, it shall be paid on or before Friday, 8 August 2025. Sun Pharmaceutical Industries is the worlds leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.
